Clinical & translational oncology

• 

  Año 2025, Vol. 27, Número 3

  • Review Article

    • Evaluation of normal tissue complications in breast cancer re‑irradiation: a meta‑analysis study

      Azadeh Amraee, Y. Mokhayeri, Mohammad Reza Gholami, S. Resane, M. R. Evazi, M. Abbasi, M. Sadr, Sh. Shamsi, P. Tayebzadeh, A. Jahani, L. Darvish

      • Resumen

      págs. 805-815

      

    • Management of typical and atypical metastatic lung carcinoids: present and future perspectives

      Ana Rodrigues, Rui Henrique, Carmen Jerónimo, António Araújo

      • Resumen

      págs. 816-823

      

    • Clinical practice guidelines for the treatment of Ewing sarcoma (Spanish Sarcoma Research Group‑GEIS)

      Cristina Mata, Ana Sebio, Javier Orcajo Rincón, Javier Martín Broto, Juan Antonio Martín Benlloch, David Marcilla Plaza, Antonio López Pousa, I. Gracia Alegría, Martina Giuppi, Erika Collado Ballesteros, Daniel Bernabeu Taboada, Enrique de Alava, Claudia M. Valverde

      • Resumen

      págs. 824-836

      

    • Advancements in second‑line treatment research for hepatocellular carcinoma

      Ruirui Sun, Chenrui Wu, Yang Gou, Yaowu Zhao, Ping Huang

      • Resumen

      págs. 837-857

      

    • Current state of proton therapy for tumors of the central nervous system in Spain: physical bases, indications, controversies and perspectives

      E. Mª. Corrales García, José Javier Aristu Mendioroz, Juan Castro Novais, Raul Matute, Mª Concepción Learra Martínez, P. D. Delgado López

      • Resumen

      págs. 858-870

      

    • The battle within: cell death by phagocytosis in cancer

      Lujia Zhou, Shiying Fan, Wenjie Zhang, Zhiyuan Gong, Daorong Wang, Dong Tang

      • Resumen

      págs. 871-886

      

    • Targeting MELK in tumor cells and tumor microenvironment: from function and mechanism to therapeutic application

      Pengfei Su, Qiliang Lu, Yuanyu Wang, Yiping Mou, Weiwei Jin

      • Resumen

      págs. 887-900

      

    • SLAM family‑mediated crosstalk between tumor and immune cells in the tumor microenvironment: a promising biomarker and a potential therapeutic target for immune checkpoint therapies

      Louis Boafo Kwantwi

      • Resumen

      págs. 901-908

      

  • Special Article

    • Beyond cancer treatment: dermo‑aesthetic and other wellness recommendations for breast cancer patients

      Alejandro Falcón González, Isabel Gallegos, Encarnación González Flores, Elena Galve Calvo, Julia Ruiz Vozmediano, Paloma Domingo García, Ricardo Lopez Martos, Elena Sanchez Rivas, Carmen Iglesias Urraca, A.I. Gómez Calvo, Amaia Mariscal, Rocío Ramos Medina, María Rivero Marcotegui, Virginia Martínez Marín

      • Resumen

      págs. 909-934

      

  • Research Article

    • Characterization of SUSD3 as a novel prognostic biomarker and therapeutic target for breast cancer

      Yan Ming Dong, Guo Qiang Bao

      • Resumen

      págs. 935-949

      

    • Signifcance of phosphoinositide 3‑kinase inhibitors in advanced breast cancer: a systematic review and meta‑analysis

      Asma Naqi, Mohammad Ahmed Khan, Abul Kalam Najmi

      • Resumen

      págs. 950-959

      

    • Efect of HER2‑low status on brain metastasis‑free survival and survival after brain metastasis in patients with breast cancer

      Tuğba Önder, Cengiz Karacin

      • Resumen

      págs. 960-973

      

    • Association of tumor‑infltrating lymphocytes with clinical outcomes in patients with triple‑negative breast cancer receiving neoadjuvant chemotherapy: a systematic review and meta‑analysis

      Francisco Cezar Aquino de Moraes, María Eduarda Di Cavalcanti Alves de Souza, Vitor Kendi Tsuchiya Sano, Rachel Arantes Moraes, Ana C. Melo

      • Resumen

      págs. 974-987

      

    • Overexpression of cytoplasmic poly(A)‑binding protein 1 as a biomarker for the prognosis and selection of postoperative regimen in breast cancer

      Yunqiu Wu, Yi Quan, Dan Zhou, Yixian Li, Xue Wen, Jun Liu, Wenbo Long

      • Resumen

      págs. 988-999

      

    • Single‑cell RNA sequencing and cell–cell communication analysis reveal tumor microenvironment associated with chemotherapy responsiveness in ovarian cancer

      Xiaoyang Jiang, Ningxuan Chen, Qinglv Wei, Xin Luo, Xiaoyi Liu, Lingcui Xie, Ping Yi, Jing Xu

      • Resumen

      págs. 1000-1012

      

    • PPM1F regulates ovarian cancer progression by afecting the dephosphorylation of ITGB1

      Yahui Leng, Zhenzi Luan, Zihang Li, Yongqing Ma, Yang Zhou, Jiaqi Liu, Song Liu, Tian Tian, Wenxiao Feng, Yanni Liu, Qin Shi, Chengyang Huang, Xuan Zhao, Wenlong Wang, Ao Liu, Tianhang Wang, Qiulei Ren, Jiakun Liu, Qian Huang, Yaling Zhang, Bin Yin, Jialin Chen, Liangliang Yang, Shiyun Zhao, Ruoyi Bao, Xingyu Ji, Yuewen Xu, Liaoyuan Liu, Junsuo Zhou, Miao Chen, Wenhui Ma, Li Shen, Te Zhang, Hongyan Zhao

      • Resumen

      págs. 1013-1025

      

    • Clinical efficacy and safety of immune checkpoint inhibitors plus anlotinib as secondline or subsequent therapy in extensive stage small cell lung cancer: a retrospective study

      Yanan Wu, Yan Zhang, Yuanjing Tian, Yajuan Lv, Jiandong Zhang

      • Resumen

      págs. 1026-1038

      

    • Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non‑small‑cell lung cancers: a multicenter prospective study

      Maria Arnal Rondan, A. Sánchez, David Lorente Estellés, José García Sánchez, Francisco Aparisi Aparisi, Jorge Soler López, Raquel Ten Benajes, Regina Gironés Sarrió

      • Resumen

      págs. 1039-1046

      

    • Quality of care assessment for non‑small cell lung cancer patients: transforming routine care data into a continuous improvement system

      J. C. Sánchez González, Beatriz Núñez García, Yago Garitaonaindia, V. Calvo de Juan, Arturo José Ramos Martín Vegue, Ana Royuela Vicente, Marta Manso Manrique, Blanca Cantos Sánchez de Ibargüen, Miriam Méndez García, Ana Collazo Lorduy, Mariano Provencio Pulla, Mariola Blanco Clemente

      • Resumen

      págs. 1047-1061

      

    • The progress of tumor vaccines clinical trials in non‑small cell lung cancer

      Xiaomu Wang, Yunping Niu, Fang Bian

      • Resumen

      págs. 1062-1074

      

    • Clinical signifcances of TTF‑1, neuroendocrine (chromogranin, synaptophysin, CD56), and keratin (pancytokeratin, CK7, CK5/6) marker immunostaining in small cell lung cancer

      Faruk Tas, Akin Ozturk, Kayhan Erturk

      • Resumen

      págs. 1075-1083

      

    • Quantitative parameters of HRCT target scan to predict the risk of lung adenocarcinoma based on the detection of lung ground‑glass nodules

      Jingfang Zhang, Peili Peng

      • Resumen

      págs. 1084-1091

      

    • Clinicopathological and prognostic value of tertiary lymphoid structures in lung cancer: a meta‑analysis

      Luyao Ma, Xiaobing Qin, Aoyang Yu, Haonan Liu, Di Pan, Ying Gao, Zichen Wu, Zihan Chen, Zhengxiang Han

      • Resumen

      págs. 1092-1104

      

    • Investigating the impact of the infammatory immune microenvironment and steroids or COX‑2 inhibitors usage on immunotherapy in advanced esophageal squamous cell carcinoma (ESCC): a propensity score matched analysis

      Huihui Li, Ning Chen, Wenjing Wang, Lisha Ye, Yun Fan, Xiaoling Wu

      • Resumen

      págs. 1105-1117

      

    • Prognostic value of a novel myeloid‑to‑lymphoid ratio biomarker in advanced gastric cancer

      Yuting Pan, Yue Ma, Guanghai Dai

      • Resumen

      págs. 1118-1130

      

    • Impact of microwave ablation on survival rates and recurrence in hepatic malignant tumors

      Jutian Shi, Yutian Jiang, Jinpeng Li, Hua Chen, Ning Cong

      • Resumen

      págs. 1131-1141

      

    • Clinical predictive factors of the efcacy of immune checkpoint inhibitors and kinase inhibitors in advanced hepatocellular cancer

      Yunyun Lu, Yi Lu

      • Resumen

      págs. 1142-1154

      

    • Changes in systemic immune‑infammation index (SII) predict the prognosis of patients with hepatitis B‑related hepatocellular carcinoma treated with lenvatinib plus PD‑1 inhibitors

      Yang Yao, Minyue Zhang, Di Liu, Xiaoni Liu, Quanwei Li

      • Resumen

      págs. 1155-1165

      

    • A mutational signature and ARID1A mutation associated with outcome in hepatocellular carcinoma

      Wei Zhou, Hao Chi, Xiaohu Zhao, Guangrong Tao, Jianhe Gan

      • Resumen

      págs. 1166-1175

      

    • Real‑world dosing patterns of regorafenib for patients with metastatic colorectal cancer in Spain: the RE‑SEARCH study

      Ana María López Muñoz, Encarnación González Flores, Alberto Carral Maseda, Paola Patricia Pimentel Cáceres, Ruth Afonso, Carlos López López, Raquel Jimeno Maté, Juan José Reina Zoilo, Carmen Castañón López, Mercedes Salgado Fernández, Jorge Aparicio Urtasun, Elena Asensio Martínez, Teresa Martín Gómez

      • Resumen

      págs. 1176-1184